Australia may subsidise Wegovy to combat obesity crisis under PBS plan

A push to add weight-loss drugs to Australia’s Pharmaceutical Benefits Scheme (PBS) has gained momentum. Health Minister Mark Butler has received expert recommendations to subsidise Wegovy, a medication designed to treat obesity. The move could provide relief for millions struggling with weight issues across the country.

Wegovy, produced by Danish company Novo Nordisk, contains the same active ingredient as Ozempic, a drug initially developed for diabetes in 2017. Both medications have since gained global attention for their effectiveness in weight management. Minister Butler has called them 'an extraordinary innovation' reshaping obesity treatment worldwide.

Around six million Australians live with obesity, many of whom could benefit from subsidised access. Currently, over 400,000 people pay out-of-pocket for these drugs, with annual costs soaring as high as $5000. Listing Wegovy on the PBS would significantly reduce this financial burden.

The proposed change, however, comes with a steep price tag. Including weight-loss medications on the PBS would cost taxpayers billions each year, placing considerable strain on the federal budget. Despite this, the government has pledged to follow all recommendations from the expert panel.

Further challenges remain as demand for these drugs continues to grow. Expanding access will require careful planning to ensure sustainability and fair distribution across the healthcare system.

If approved, the PBS listing would mark a major shift in obesity treatment for Australians. Patients with a BMI of 35 and existing cardiovascular conditions would gain subsidised access to Wegovy. The decision now rests on balancing healthcare benefits with long-term budget impacts.